1. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients
- Author
-
Patrizia Maria Baldini, Paola Mainquà, Alessandro Caraffa, Donatella Dennetta, Francesca Fulgenzi, M. Mancini, Antonio Polenta, Lorenzo Gasperoni, Gabriele Frausini, Massimo Mattioli, Luciano Mucci, Samuele Bedetta, and Devis Benfaremo
- Subjects
Male ,Gastrointestinal bleeding ,medicine.medical_specialty ,Blood transfusion ,medicine.drug_class ,medicine.medical_treatment ,Low molecular weight heparin ,030204 cardiovascular system & hematology ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Coagulopathy ,Humans ,Medicine ,030212 general & internal medicine ,Enoxaparin ,Aged ,Retrospective Studies ,Aged, 80 and over ,Heparin ,SARS-CoV-2 ,business.industry ,Bleeding ,COVID-19 ,Thrombosis ,Pneumonia ,Hematology ,Middle Aged ,medicine.disease ,COVID-19 Drug Treatment ,Pulmonary embolism ,Italy ,Kidney Failure, Chronic ,Female ,Safety ,business ,Cardiology and Cardiovascular Medicine ,Follow-Up Studies ,medicine.drug - Abstract
Coagulopathy represents one of the most important determinants of morbidity and mortality in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or higher doses are needed, especially in severe patients, is unknown. To evaluate the safety of intermediate dose regimens of low-weight molecular heparin (LWMH) in COVID-19 patients with pneumonia, particularly in older patients. We retrospectively evaluated 105 hospitalized patients (61 M, 44 F; mean age 73.7 years) treated with subcutaneous enoxaparin: 80 mg/day in normal weight and mild-to-moderate impair or normal renal function; 40 mg/day in severe chronic renal failure or low bodyweight (
- Published
- 2020
- Full Text
- View/download PDF